Savient Pharmaceuticals (SVNT +4.4%) says new data presented at the European League Against...

|About: Savient Pharmaceuticals, Inc. (SVNTQ)|By:, SA News Editor

Savient Pharmaceuticals (SVNT +4.4%) says new data presented at the European League Against Rheumatism congress showed patients with refractory chronic gout also suffering from chronic kidney disease responded to treatment with its drug Krystexxa regardless of its baseline chronic kidney disease stage. The company is seeking approval for Krystexxa in Europe.